

## U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 1  
Corrected Copy**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Wyandotte Internal Medicine Associates, PLLC</p> <p>2. 1700 Biddle Avenue Wyandotte, MI 48192</p>	<p>In accordance with the letter dated <b>August 31, 2004</b>, and the facsimile letter received <b>December 6, 2004</b>,</p> <p>3. License number 21-32495-01 is amended in its entirety or read as follows:</p> <p>4. Expiration date April 30, 2014</p> <p>5. Docket No. 030-36514 Reference No.</p>
---	---

- |  |   |   |
|--|---|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.200</p> | <p>7. Chemical and/or physical form</p> <p>A. Any (excluding generators, aerosols and xenon), limited to cardiovascular clinical procedures</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> |
|--|---|---|

9. Authorized use:
- A. Imaging and localization studies permitted by 10 CFR 35.200 (excluding generators, aerosols and xenon), limited to cardiovascular clinical procedures.

CONDITIONS

10. Licensed material shall be used only at the licensee's facility located at 1700 Biddle Avenue, Wyandotte, Michigan.
11. The Radiation Safety Officer for this license is **Subrahmanya S. Yellayi, M.D.**
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized Users**Subrahmanya S. Yellayi, M.D.**Material and Use

10 CFR 35.200 (excluding generators, aerosols and xenon), limited to cardiovascular clinical procedures.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
21-32495-01Docket or Reference Number  
030-36514Amendment No. 1  
**Corrected Copy**

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated February 12, 2004;
  - B. Letter dated February 6, 2004;
  - C. Facsimile letter dated April 23, 2004; and
  - D. **Facsimile letter received December 6, 2004.**

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date SEP 13 2012

By

William P. Reichhold  
Materials Licensing Branch  
Region III